While I mentioned a few days back this impending announcement was a positive sign for Opthea there are are definitely no certainties in biotech investing and this goes for Opthea going forward. It's a very risky business. RAP, MSB and FTT have been negatively impacted to varying degrees by trial results that have not met all end points, or in the case of FTT a therapy that was effectively proved to be no better than the the placebo. My heart goes out to FTT holders some of which lost 6 figure sums on their holdings.
Ann: Opthea Phase 2b wAMD trial fully recruited ahead of schedule, page-2
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |